Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (IgG-Fv) is formed by an Immunoglobulin G (IgG) and a fragment variable Fv region, in which the Fc of IgG is engineered by KIH. The Fv region of an anti-CD3 antibody variable domain is fused to the C terminal of an IgG of anti-EGFR antibody, or vice versa. The format retains desired characteristics of intact antibodies. This BsAb can retarget T cells to tumor cells. It is designed for the research of Head and neck cancer; Colorectal cancer (CRC); Glioblastoma multiforme (GBM); Squamous cancer; Glioblastoma; Medulloblastoma; Non-small cell lung cancer (NSCLC); Renal cell cancer (RCC); Solid tumors therapy.
There are currently no customer reviews or questions for Recombinant Anti-CD3 x Anti-EGFR Bispecific Antibody (IgG-Fv) (BSGV-077). Click the button below to contact us or submit your feedback about this product.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRYSERVICES
PRODUCTS
PLATFORMS